Coherus Oncology (CHRS) partners with Janssen on Phase 1b mCRPC combo trial

Rhea-AI Filing Summary

Coherus Oncology, Inc. entered into a clinical supply agreement with Janssen Research & Development, LLC to support a Phase 1b study in metastatic castration-resistant prostate cancer. The trial will evaluate Coherus’ investigational anti-CCR8 cytolytic monoclonal antibody tagmokitug (CHS-114) in combination with Janssen’s T-cell engaging bispecific antibody pasritamig.

Under the agreement, Janssen will supply pasritamig, while Coherus will act as sponsor of the Phase 1b clinical trial in patients with metastatic castration-resistant prostate cancer. Each company keeps all commercial rights to its own compound, whether used alone or in combination therapies.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

0001512762false00015127622026-02-042026-02-04

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

​

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): February 4, 2026

​

​

COHERUS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

​

​

Delaware		001-36721		27-3615821
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

​

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

​

Registrant’s telephone number, including area code: (650) 649-3530

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Common Stock, $0.0001 par value per share		CHRS		The Nasdaq Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company  ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

​

​

​

Item 8.01 Other Events.

​

On February 4, 2026, Coherus Oncology, Inc. (the “Company”) announced a clinical supply agreement with Janssen Research & Development, LLC (“Janssen”), to evaluate tagmokitug (CHS-114), the Company’s investigational anti-CCR8 cytolytic monoclonal antibody, in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer (mCRPC).

Under the terms of the clinical supply agreement, Janssen will provide pasritamig to the Company, who will be the sponsor of the Phase 1b clinical trial. Janssen and the Company each retain all commercial rights to their respective compounds, including as monotherapy or as combination treatments.

​

​

​

​

​

​

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​	​
Date: February 4, 2026	​ ​ ​	COHERUS ONCOLOGY, INC.
​	​	​	​
​	​	By:	/s/ Dennis M. Lanfear
​	​	Name:	Dennis M. Lanfear
​	​	Title:	Chief Executive Officer

​

​

​

​

FAQ

What did Coherus Oncology (CHRS) announce in this 8-K filing?

Coherus Oncology announced a clinical supply agreement with Janssen Research & Development, LLC. The collaboration supports a Phase 1b trial testing tagmokitug (CHS-114) with Janssen’s pasritamig in patients with metastatic castration-resistant prostate cancer.

Which drugs are involved in Coherus Oncology’s agreement with Janssen?

The agreement covers tagmokitug (CHS-114), Coherus’ investigational anti-CCR8 cytolytic monoclonal antibody, and pasritamig, Janssen’s T-cell engaging bispecific antibody. These will be evaluated together in a Phase 1b study in metastatic castration-resistant prostate cancer.

What cancer indication is targeted in the Coherus–Janssen Phase 1b study?

The Phase 1b clinical study targets patients with metastatic castration-resistant prostate cancer. Coherus will sponsor the trial, evaluating tagmokitug (CHS-114) in combination with Janssen’s bispecific antibody pasritamig in this advanced prostate cancer setting.

Who will sponsor the Phase 1b clinical trial described by Coherus Oncology (CHRS)?

Coherus Oncology will be the sponsor of the Phase 1b clinical trial. Under the supply agreement, Janssen provides pasritamig, while Coherus oversees the study evaluating the combination in metastatic castration-resistant prostate cancer patients.

How are commercial rights handled in the Coherus–Janssen supply agreement?

Each party keeps all commercial rights to its own compound. Coherus retains rights to tagmokitug (CHS-114) and Janssen retains rights to pasritamig, including for use as monotherapy or in combination treatments.

Is the Coherus–Janssen collaboration a full partnership or limited to clinical supply?

The arrangement is a clinical supply agreement. Janssen will provide pasritamig for a Coherus-sponsored Phase 1b trial, and both companies retain full commercial rights to their respective compounds, including potential monotherapy or combination uses.